# A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)

> **NCT00676702** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 13 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency
- Pancreatitis, Chronic
- Steatorrhea
- Pancreatitis

## Interventions

- **DIETARY_SUPPLEMENT:** Ensure Plus
- **DRUG:** Pancrelipase in combination with Ensure Plus

## Key facts

- **NCT ID:** NCT00676702
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00676702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00676702, "A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00676702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*